Migraine

The premonitory constellation of neurologic, autonomic, and behavioral symptoms are increasingly understood as the earliest manifestations of migraine pathophysiology.

The investigational ShiraTronics Migraine Therapy System delivered an average of 9.6 migraine-free days per month, reduced rescue medication use, and improved QOL.

Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.

The superior tolerability and efficacy of the CGRP-targeting atogepant supports recent calls from the AHS to consider the class as first-line preventive therapy for migraine.

New data from UNITE study suggest fremanezumab was effective in alleviating migraine and comorbid MDD in patients with both conditions.

The only approved DHE nasal powder addresses persistent limitations of existing DHE formulations, including liquid nasal sprays and injectables, Satsuma stated.

Subgroup analyses found no significant difference in efficacy based on change in therapeutic action (ie, CGRP vs its receptor), doses, or intertreatment interval.

CT-132 is a 12-week app-based intervention that uses validated behavioral techniques to modulate labile brain circuitry involved in migraine, according to Click Therapeutics.

A new study compared health care utilization and costs between adults initially misdiagnosed followed by a correct diagnosis of migraine and those whose first diagnosis was accurate.

While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.